HK1090093A1 - Method of selecting patients suitable for wt1 vaccine - Google Patents

Method of selecting patients suitable for wt1 vaccine

Info

Publication number
HK1090093A1
HK1090093A1 HK06110635.4A HK06110635A HK1090093A1 HK 1090093 A1 HK1090093 A1 HK 1090093A1 HK 06110635 A HK06110635 A HK 06110635A HK 1090093 A1 HK1090093 A1 HK 1090093A1
Authority
HK
Hong Kong
Prior art keywords
vaccine
selecting patients
biological sample
precursor cells
highly responsive
Prior art date
Application number
HK06110635.4A
Other languages
English (en)
Inventor
Haruo Sugiyama
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of HK1090093A1 publication Critical patent/HK1090093A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
HK06110635.4A 2003-06-27 2006-09-22 Method of selecting patients suitable for wt1 vaccine HK1090093A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003184436 2003-06-27
JP2004070497 2004-03-12
PCT/JP2004/009378 WO2005001117A1 (fr) 2003-06-27 2004-06-25 Procede de selection d'un patient s'adaptant au vaccin anti-wt1

Publications (1)

Publication Number Publication Date
HK1090093A1 true HK1090093A1 (en) 2006-12-15

Family

ID=33554467

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06110635.4A HK1090093A1 (en) 2003-06-27 2006-09-22 Method of selecting patients suitable for wt1 vaccine

Country Status (10)

Country Link
US (1) US10500257B2 (fr)
EP (3) EP2338509B1 (fr)
JP (1) JP4566912B2 (fr)
KR (2) KR101431312B1 (fr)
CN (1) CN1842603B (fr)
AT (1) ATE538809T1 (fr)
CA (2) CA2893995A1 (fr)
ES (3) ES2478446T3 (fr)
HK (1) HK1090093A1 (fr)
WO (1) WO2005001117A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
CA2440303C (fr) 2001-03-22 2013-03-19 Haruo Sugiyama Peptide modifie wt1
EP1550453B1 (fr) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Preparation de peptides antigenes du cancer
EP2338509B1 (fr) 2003-06-27 2014-06-18 International Institute of Cancer Immunology, Inc. Procédé de selection d'un patient s'adaptant au vaccin WT1
KR20130062368A (ko) 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
PL1731605T3 (pl) * 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
CA2626238C (fr) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Peptides de liaison wt1 hla de classe ii, compositions et methodes associees comprenant ces peptides
CA2631292C (fr) * 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Peptides antigenes de cancer wt1 derives et leur utilisation
EP3834836A1 (fr) 2006-04-10 2021-06-16 Memorial Sloan Kettering Cancer Center Peptides wt-1 immunogènes et leurs utilisations
AU2007256383B2 (en) * 2006-06-02 2013-06-06 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
NZ599161A (en) 2007-02-27 2012-07-27 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
EP3173480A3 (fr) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Gène du récepteur des lymphocytes t spécifiques de l'antigène du cancer, peptide codé par le gène et utilisation de ceux-ci
US8557779B2 (en) * 2007-12-05 2013-10-15 International Institute Of Cancer Immunology, Inc. Cancer vaccine composition
TW201623616A (zh) 2010-10-05 2016-07-01 癌免疫研究所股份有限公司 用於活化細胞毒性ｔ細胞的方法及組成物，及用於細胞毒性ｔ細胞之活化誘導物
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
EP2561759A1 (fr) 2011-08-26 2013-02-27 Bayer Cropscience AG 2-amidobenzimidazoles fluoroalkyl substitués et leur effet sur la croissance des plantes
CN103917097A (zh) 2011-09-16 2014-07-09 拜耳知识产权有限责任公司 5-苯基-或5-苄基-2-异噁唑啉-3-甲酸酯用于改善植物产量的用途
JP6138797B2 (ja) 2011-09-16 2017-05-31 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 植物収量を向上させるためのアシルスルホンアミド類の使用
MX362112B (es) 2011-09-16 2019-01-07 Bayer Ip Gmbh Uso de fenilpirazolin-3-carboxilatos para mejorar el rendimiento de las plantas.
EP2802347B1 (fr) 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Peptides wt-1 immunogènes et leurs procédés d'utilisation
US9226955B2 (en) 2012-10-23 2016-01-05 Ubivac, Llc Allogeneic autophagosome-enriched composition for the treatment of disease
NZ708990A (en) 2012-12-17 2020-03-27 Int Inst Cancer Immunology Inc Method for activating helper t cell
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN116789792A (zh) * 2013-01-15 2023-09-22 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
BR112015021132B1 (pt) 2013-03-05 2020-11-03 Bayer Cropscience Aktiengesellschaft uso de 1-metilhexil(5-cloro-8-quinolinóxi)acetato para induzir uma resposta de regulação de crescimento em plantas
ES2748350T3 (es) 2013-03-05 2020-03-16 Bayer Cropscience Ag Uso de N-(2-metoxibenzoil)-4-[metilaminocarbonil)amino]bencenosulfonamida en combinación con un insecticida o fungicida para mejorar el rendimiento en plantas
RU2015146210A (ru) * 2013-03-28 2017-05-03 Сентр Оспиталье Юниверситер Де Монпелье Способ определения чувствительности к радиоактивному облучению
ES2954899T3 (es) * 2013-05-13 2023-11-27 Int Inst Cancer Immunology Inc Procedimiento para predecir el efecto clínico de una inmunoterapia
WO2017087857A1 (fr) 2015-11-20 2017-05-26 Memorial Sloan Kettering Cancer Center Procédés et compositions pour le traitement du cancer
EP3318135A1 (fr) 2016-11-03 2018-05-09 Perfetti Van Melle S.p.A. Matériau de bonbon effervescent, son procédé de préparation et produits fabriqués à partir de celui-ci
CA3182959A1 (fr) * 2020-05-12 2021-11-18 Sumitomo Pharma Co., Ltd. Composition pharmaceutique pour le traitement du cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923799A (en) 1984-02-06 1990-05-08 The Ontario Cancer Institute T cell specific cDNA clone
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
EP0602178A4 (en) 1991-08-28 1995-10-25 Wistar Inst T cell receptor-based therapy for rheumatoid arthritis.
US5364787A (en) 1992-03-23 1994-11-15 Idaho Research Foundation Genes and enzymes involved in the microbial degradation of pentachlorophenol
US6225051B1 (en) 1996-04-16 2001-05-01 Haruo Sugiyama Method of detecting solid cancer cells and tissue atypia and method of testing tissues for use in bone marrow transplantation and peripheral blood stem cell transplantation
GB9710820D0 (en) 1997-05-27 1997-07-23 Univ Dundee Immunological method
US6013444A (en) 1997-09-18 2000-01-11 Oligotrail, Llc DNA bracketing locus compatible standards for electrophoresis
AU5528198A (en) 1997-12-03 1999-06-16 Immune Response Corporation, The Vaccination and methods against multiple sclerosis using specific tcr vbeta peptides
SK17332000A3 (sk) 1998-05-19 2001-06-11 Avidex Limited Preskladaný rekombinantný t bunkový receptor-tcr, sekvencie nukleových kyselín, ktoré kódujú rekombinantné tcr reťazce rekombinantného tcr, a spôsob jeho výroby
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
CZ20011144A3 (cs) 1998-09-30 2002-06-12 Corixa Corporation Prostředky a způsoby pro WT1 specifickou imunoterapii
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
NZ513630A (en) 1999-02-23 2001-09-28 Baylor College Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
CA2440303C (fr) 2001-03-22 2013-03-19 Haruo Sugiyama Peptide modifie wt1
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
WO2003025569A1 (fr) 2001-09-18 2003-03-27 Kyogo Itoh Procede de detection de l'immunite cellulaire et son application sur des medicaments
EP1447092A4 (fr) 2001-09-28 2007-07-11 Haruo Sugiyama Methodes d'induction de lymphocytes t specifiques d'un antigene
WO2003028757A1 (fr) 2001-09-28 2003-04-10 Haruo Sugiyama Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
WO2003059155A2 (fr) 2002-01-09 2003-07-24 Maxx Genetech Co. Ltd Procede de detection de la proliferation de lymphocytes t pour le diagnostique de maladies a l'aide d'un ensemble de genes
CN101113163B (zh) 2002-06-12 2010-10-06 株式会社国际癌症免疫研究所 Hla-a24限制性癌抗原肽
EP1550453B1 (fr) * 2002-09-12 2015-05-27 International Institute of Cancer Immunology, Inc. Preparation de peptides antigenes du cancer
WO2004063706A2 (fr) 2003-01-08 2004-07-29 Maxx Genetech Co., Ltd. Procede permettant de detecter la surexpression des genes du recepteur des lymphocytes t par pcr en temps reel
EP2338509B1 (fr) 2003-06-27 2014-06-18 International Institute of Cancer Immunology, Inc. Procédé de selection d'un patient s'adaptant au vaccin WT1
KR20130062368A (ko) 2003-11-05 2013-06-12 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 유래의 ｈｌａ-ｄｒ 결합성 항원 펩티드
WO2005053603A2 (fr) 2003-12-08 2005-06-16 Yeda Research And Development Co. Ltd. Typage d'une region variable du recepteur de l'antigene
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
PL1731605T3 (pl) 2004-03-31 2010-08-31 Int Inst Cancer Immunology Inc Nowotworowe peptydy antygenowe pochodzące z WT1
GB0411771D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Nucleoproteins displaying native T cell receptor libraries
GB0427585D0 (en) 2004-12-16 2005-01-19 Avidex Ltd Assay
WO2008026927A2 (fr) 2006-08-30 2008-03-06 Academisch Medisch Centrum Procédé d'affichage des répertoires des récepteurs des lymphocytes t et b
EP3173480A3 (fr) 2007-03-05 2017-08-16 International Institute of Cancer Immunology, Inc. Gène du récepteur des lymphocytes t spécifiques de l'antigène du cancer, peptide codé par le gène et utilisation de ceux-ci
JP2009278927A (ja) 2008-05-23 2009-12-03 Tohoku Univ Ｔ細胞受容体を模倣する抗体断片及びその製造方法
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell

Also Published As

Publication number Publication date
EP2343083B1 (fr) 2014-01-15
EP2338509A3 (fr) 2011-11-30
KR20060069363A (ko) 2006-06-21
JPWO2005001117A1 (ja) 2006-08-10
EP2338509B1 (fr) 2014-06-18
CA2530184C (fr) 2015-10-06
WO2005001117A1 (fr) 2005-01-06
ES2443582T3 (es) 2014-02-19
ES2478446T3 (es) 2014-07-22
KR101292971B1 (ko) 2013-08-12
CA2530184A1 (fr) 2005-01-06
KR101431312B1 (ko) 2014-08-20
EP1640458A4 (fr) 2008-05-21
KR20110049877A (ko) 2011-05-12
CN1842603A (zh) 2006-10-04
US10500257B2 (en) 2019-12-10
EP2343083A2 (fr) 2011-07-13
EP2338509A2 (fr) 2011-06-29
CN1842603B (zh) 2013-09-11
EP2343083A3 (fr) 2011-08-03
EP1640458B1 (fr) 2011-12-28
ES2378156T3 (es) 2012-04-09
EP1640458A1 (fr) 2006-03-29
US20070128207A1 (en) 2007-06-07
JP4566912B2 (ja) 2010-10-20
ATE538809T1 (de) 2012-01-15
CA2893995A1 (fr) 2005-01-06

Similar Documents

Publication Publication Date Title
HK1090093A1 (en) Method of selecting patients suitable for wt1 vaccine
RU2007141067A (ru) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
EP1561106A4 (fr) Methode diagnostique permettant de mesurer une reponse immunitaire a mediation cellulaire
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2004091384A3 (fr) Complexes de recepteurs de surface erbb utilises comme biomarqueurs
MX2010006484A (es) Composiciones y metodos para detectar anticuerpos de infidelidad de transcripcion (tiab).
JP2014512006A5 (fr)
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
Chonanant et al. Characterisation of chondrogenic differentiation of human mesenchymal stem cells using synchrotron FTIR microspectroscopy
WO2005040421A3 (fr) Marqueurs de pronostic et de diagnostic des troubles de proliferation cellulaire dans les tissus mammaires
WO2012044696A3 (fr) Prédiction de résultats cliniques dans des malignités hématologiques au moyen d'une signature de l'expression d'auto-renouvellement
EA201590686A1 (ru) Тест на митохондриальную токсичность
DE50300981D1 (de) Verfahren und Vorrichtung zur Messung von Blutgasparametern
WO2006023563A3 (fr) Dispositif d'imagerie diagnostique pour analyser des cellules rares circulantes
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
ATE514951T1 (de) Verfahren zur prüfung eines mehrkanaligen elements zur blutanalyse
CN207488145U (zh) 一种血液肿瘤用检测装置
WO2007071829A3 (fr) Méthodes et moyens relatifs à des maladies
EP1600513A4 (fr) Procede pour analyser une cellule
EP2539709A4 (fr) Altérations propres à la maladie d'alzheimer des niveaux de protéine kinase c epsilon (pkc-epsilon)
FR2846426B1 (fr) Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
Hu et al. Detection of hypoxic fractions in murine tumors by comet assay: comparison with other techniques
WO2012032511A3 (fr) Kit de surveillance, dépistage et stadification de la maladie du greffon contre l'hôte
EP1988164A4 (fr) Procédé destiné à tester la sensibilité d'un cancer solide contre un inhibiteur de tyrosine kinase et nécessaire de test correspondant
WO2005040806A3 (fr) Utilisation de la protéine asc comme marqueur du cancer du sein

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200625